Relief Therapeutics Holding AG (RLFTF)

[djhfsu]

In the recent news article on Aviptadil in Nebraska hospital, the infectious disease doctor, Dr. Eduardo Freitas, "emphasized that aviptadil isn’t a silver bullet and that studies are needed before the medication can be used widely to treat COVID-19.".

I'm curious what everyone thinks about this statement. The NBC video about the same patient seemed very optimistic. I wonder if the doctor made that statement because of the patient population (severe to critical) and that the disease creates other problems for the patients. If Aviptadil is used earlier in the disease onset (i.e. when a patient presents at the hospital), maybe the doctor would think differently if the disease is not allowed to damage other parts of the body.

Just thinking out loud.

Thoughts?

Dave